Overview

Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Status:
Completed
Trial end date:
2001-10-01
Target enrollment:
0
Participant gender:
Female
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining cisplatin and irinotecan in treating patients who have ovarian, fallopian tube, or peritoneal cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Camptothecin
Cisplatin
Irinotecan
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed epithelial carcinoma of the ovary,
fallopian tube, or peritoneum At least 3 prior courses of standard platinum-paclitaxel
regimen Patients with taxane allergy may enter this study after 3 courses of platinum based
treatment CA125 at least 35 measured within 30 days of commencement of treatment Measurable
disease not required No CNS metastases, carcinomatous meningitis or interstitial pulmonary
fibrosis

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life
expectancy: Not specified Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count
at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no
greater than 1.5 mg/dL Calcium less than 12.0 mg/dL Cardiovascular: No unstable angina No
New York Heart Association grade III or IV cardiac disease Pulmonary: See Disease
Characteristics Other: No active or uncontrolled infection No history of seizures No known
Gilbert's Disease No medical or psychiatric conditions that makes patient a poor risk for
participation in this study Not pregnant or lactating Negative pregnancy test

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy Chemotherapy: No prior
irinotecan or topotecan Endocrine therapy: Not specified Radiotherapy: No prior
radiotherapy to the pelvis Surgery: At least 4 weeks since prior surgery and recovered
Other: No concurrent phenytoin, phenobarbital, or other antiepileptic prophylaxis